Xilio Therapeutics (XLO) Projected to Release Earnings on Thursday

Xilio Therapeutics (NASDAQ:XLO) will likely be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Xilio Therapeutics to announce earnings of ($0.59) per share and revenue of $12.72 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 9:30 AM ET.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.08. The company had revenue of $12.65 million for the quarter, compared to the consensus estimate of $8.52 million. Xilio Therapeutics had a negative net margin of 58.52% and a negative return on equity of 151.42%.

Xilio Therapeutics Stock Up 0.3%

Xilio Therapeutics stock opened at $9.20 on Tuesday. The company has a market cap of $60.54 million, a price-to-earnings ratio of -2.59 and a beta of -0.14. The firm’s fifty day moving average is $8.82 and its 200 day moving average is $8.36. Xilio Therapeutics has a 52-week low of $6.47 and a 52-week high of $12.74.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on XLO. Weiss Ratings downgraded Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Wall Street Zen lowered shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Xilio Therapeutics currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Xilio Therapeutics

A number of large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC boosted its holdings in Xilio Therapeutics by 39.6% in the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock valued at $277,000 after purchasing an additional 93,338 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Xilio Therapeutics by 68.3% during the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after buying an additional 139,716 shares during the period. Jane Street Group LLC acquired a new position in Xilio Therapeutics in the fourth quarter valued at approximately $27,000. State Street Corp lifted its holdings in Xilio Therapeutics by 13.7% in the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after acquiring an additional 22,500 shares during the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in Xilio Therapeutics in the fourth quarter worth approximately $109,000. 54.29% of the stock is currently owned by hedge funds and other institutional investors.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.